Live prices by TradingView

Industry brief

Iran's pharmaceutical industry in 2026

Published 12 November 2026 · Data to 8 November 2026 · DapezSolution research, Tehran

Key points

~400
trillion tomans in drug sales, first half of 1405 (to 22 Sep 2026)
98.9%
of units sold were made in Iran
28,500
tomans per USD, the subsidised rate for qualifying imports

1. Market size and structure

Iran's medicine market is large in local currency and small in dollars. Its nominal value grew from 10.5 trillion tomans in 1393 (2014/15) to 232.1 trillion tomans in 1403 (2024/25), a compound growth rate of about 36% a year. Volume grew only about 5.3% a year over the same period. Measured in US dollars, the market has mostly stayed in a range of 3 to 5 billion dollars, with exchange-rate shocks moving it within that range. [1]

The latest official data, from Iran's Food and Drug Administration, covers the first six months of the Iranian year 1405 (21 March to 22 September 2026): [2]

First half of 1405Value (trillion tomans)Share of valueShare of units
Domestically produced34887%98.9%
Imported5213%1.1%
Total~400100%28.3 bn units

Unit sales rose about 1.3% compared with the same period a year earlier. By value, the best-selling products were tirzepatide, a treatment for diabetes and weight loss (28.4 trillion tomans), insulin (12.1 trillion tomans) and saline solution (7.2 trillion tomans). By count, the top five were aspirin, atorvastatin, levothyroxine, metformin and amoxicillin. [2]

A simple doubling of the first-half figure gives about 800 trillion tomans for the full year. This is our rough annualisation, not an official forecast, and second-half prices may differ.

2. Where the inputs come from

Self-sufficiency stops at the formulation stage. Active pharmaceutical ingredients, excipients, packaging and production equipment are still largely imported. An analysis of 34 listed pharmaceutical producers found that cost of sales averages about 60% of operating revenue, and direct materials make up about 70% of that cost. [1] This is why the exchange rate matters so much to the sector.

The head of the Food and Drug Administration said in August that the 2026 conflict showed the industry still needs to reduce its dependence on imported raw materials, moving from "maximum to minimum imports". [3]

3. Currency policy: the main variable

Current rules

Qualifying medicine and medical imports still receive a subsidised rate of 28,500 tomans per US dollar, under an announcement made in April 2026. The rate does not apply to every imported medicine. [4]

Direction of travel

On 23 August 2026 the head of the Food and Drug Administration said the subsidised rate would not be removed this year, but that government policy is to remove it gradually. [3] On 3 November 2026 he said imported insulin is now allocated foreign exchange at the commercial market rate, and that higher prices for those products are therefore certain. [5]

What removal would mean

A published scenario analysis estimated the effect on the sector in 1405: [1]

Scenario for 1405Sector inflationMarket size (trillion tomans)
Full liberalisation of the exchange rate~71.6%~873
Single supported rate of 80,000 tomans~29.7%~660

These scenarios were published in February 2026, before the conflict. They are useful for direction, not as current estimates.

4. Shortages and prices

The core mechanism is simple. Prices are set administratively. When the cost of inputs rises and approved prices are not adjusted at the same time, producers and importers supply less. The shock appears as shortages rather than as higher prices.

5. Payments and working capital

Late payment is now a structural problem across the chain. The head of the Food and Drug Administration said in November that many hospitals have not paid their pharmaceutical suppliers for more than a year. [5] Iranian media have put insurers' debts to pharmacies at about 8 quadrillion rials, roughly 3.6 billion US dollars at the time of reporting. [6] For producers, this means more borrowing at high local interest rates to fund the gap between paying for inputs and getting paid for sales.

6. Risks

7. What to watch

Sources

  1. EcoIran, "Currency and medicine in Iran: from hidden inflation to supply disruption risk", 9 February 2026 (in Persian). ecoiran.com
  2. Mehr News Agency, citing Farhad Habibi, deputy head of Iran's Food and Drug Administration, 8 November 2026 (in Persian). mehrnews.com
  3. EcoIran, remarks by Mahdi Pirsalehi, head of Iran's Food and Drug Administration, 24 August 2026 (in Persian). ecoiran.com
  4. NIAC, "Iran's Drug Costs Rise as the Rial Falls and the Blockade Strains Supply", 9 September 2026. niacouncil.org
  5. Shahrara News, remarks by the head of Iran's Food and Drug Administration, 3 November 2026 (in Persian). shahraranews.ir
  6. Al Jazeera, "Medicine shortages grow in Iran as US tightens sanctions, blockade", 9 September 2026. aljazeera.com

This brief is research and analysis only. It does not name or assess any listed company, and it is not investment advice or a recommendation to buy or sell any security. Figures are taken from the sources listed; where sources differ, both views are shown. Iranian-year dates are converted to the Gregorian calendar.

Want a brief like this on another Iranian industry? Message @dapezsolution on X.

Questions about the data, a correction, or a custom report on another topic? Write to our research desk.

research@dapezsolutions.com